MBX Biosciences, Inc. Segments Disclosure
The Company operates as a reportable segment engaged in the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The Company's determination that it operates as a segment is consistent with the nature of its operations and the financial information regularly reviewed by the chief executive officer, in his capacity as the chief operating decision maker , for the purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. The Company's purpose is to help people with endocrine and metabolic disorders live fuller and healthier lives. The Company's long-term success is significantly dependent on its ability to research and develop innovative medicines. The CODM uses net loss to assess performance of the Company, ensuring that it is investing in the research and development of product candidates. The CODM allocates research and development resources based upon several factors, including the likelihood of technical success, unmet medical needs, and the viability of commercial success. A significant component of the CODM’s decision-making process is to ensure a balanced investment in the research and development portfolio to drive near-term success and long-term sustainability.
The following table summarizes our significant segment expenses and segment net loss:
|
|
Years ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Expenses: |
|
|
|
|
|
|
||
Canvuparatide direct program expense |
|
$ |
37,225 |
|
|
$ |
21,582 |
|
MBX 4291 direct program expense (1) |
|
|
12,653 |
|
|
$ |
10,771 |
|
Imapextide direct program expense |
|
|
4,118 |
|
|
|
11,561 |
|
Preclinical and other research and development direct expense (1) |
|
|
6,032 |
|
|
|
1,341 |
|
Research and development overhead expense |
|
|
19,131 |
|
|
|
12,160 |
|
Other segment items (2) |
|
|
7,812 |
|
|
|
4,507 |
|
Net loss |
|
$ |
86,971 |
|
|
$ |
61,922 |
|
|
|
|
|
|
|
|
||
(1) Prior period amounts for MBX 4291 have been reclassified to conform to current period presentation.
(2) Other segment items are primarily comprised of general and administrative expenses and interest and other income.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 12, 2026 | Showing above |
| 2024 | Mar 17, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.